EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients.
Recent Searches
Office
Dublin, Ireland
Mark Chalmers is a partner at Ernst & Young, in the EY Life Sciences Commercial Strategy and Market Access team, with more than 15 years of experience specializing in global commercial and launch strategy, including international pricing and market access for pharmaceutical and biotech companies.
He has global experience of health care systems and health technology assessment, with a deep knowledge of oncology, immunology, rare diseases, Advanced Therapy Medicinal Products (ATMPs) and cell and gene-based therapies.
Prior to EY, Mark worked for a number of life sciences strategy consulting firms, to address critical commercial issues and support business development and licensing decisions.
Mark has a PhD in Molecular Biology and Pharmacology from University of Cambridge.
How Mark is building a better working world
“I help Biopharma companies provide patients with access to Advanced Therapeutic Medicinal Products (ATMPs). ATMPs are groundbreaking scientific innovation, offering patients personalized, ‘potentially’ curative one-time treatments for severe diseases. Biopharma launches are complex and challenging due to the dynamic and competitive market, combined with an uncertain future clinical landscape. Payers are increasingly influential, and healthcare systems face affordability challenges. Pricing and market access hurdles need to be overcome to realize the ATMP potential value. Many ATMP global product launches underperform as patients fail to receive access. Innovative value-based contracting is critical for the success of ATMPs. Through a step-change in engagement with stakeholders across the healthcare ecosystem we ensure launch success. Data is fuelling science and technology to generate insights and treatments that are personised to the patient. I help deliver the vision of value-based healthcare, by getting innovation to more patients faster, and improving patient outcomes and experience.”